Allergy or hypersensitivity to cemiplimab or to any of its excipients;
Hypersensitivity to nivolumab, ipilimumab, or any of their excipients
Known hypersensitivity to any of the excipients of ribociclib
Subject with a history of severe hypersensitivity reactions to any of the other excipients of the protocol IMPs (see Section ..);
Hypersensitivity to the active substance or to any of the excipients
Patient has a known hypersensitivity to any of the excipients of LEE
Known hypersensitivity to drugs chemically related to tivozanib hydrochloride or sunitinib or their excipients
Known hypersensitivity to sunitinib or masitinib or to any of the excipients
Patients who have had hypersensitivity to paclitaxel or any of its excipients
Has a known severe hypersensitivity (? Grade ) to any of the study chemotherapy agents and/or to any of their excipients.
Have previously participated in any study involving a checkpoint kinase  inhibitor or have hypersensitivity to the study drug or excipients.
Known hypersensitivity to exemestane or its excipients
Hypersensitivity to nivolumab or any of its excipients.
Hypersensitivity to NKTR- or any of its excipients.
Participant has a known hypersensitivity to any of the excipients of HB-.
Patient has a known hypersensitivity to any of the excipients of ribociclib or everolimus
Patient has a known hypersensitivity to any of the excipients of LEE or everolimus
Known hypersensitivity to gemcitabine, taxanes or any of their excipients, or the patient exhibits any of the events outlined in the Contraindications or Special Warnings and Precautions sections of the product or comparator Summary of Product Characteristics or Prescribing Information. Possible hypersensitivity to napabucasin or one of the excipients which include the azo dyes sunset yellow and allura red.
Prior known hypersensitivity to any of the excipients of alpelisib
Known history, or suspected hypersensitivity to any excipients.
Known hypersensitivity to orteronel or to orteronel excipients, which are listed by formulation in the Investigator Brochure
EXCLUSION - PARTICIPANT: Participants with a history of hypersensitivity reactions to study agent or their excipients.
Participants must not have hypersensitivity to nivolumab, urelumab, cabiralizumab or any of their excipients
Has severe hypersensitivity (?Grade ) to any study therapies including any excipients
Hypersensitivity to Ipilimumab and/or nivolumab or any of its excipients
Known intolerance or hypersensitivity to any of the products used in this study or their excipients.
Known hypersensitivity to nintedanib, nivolumab, ipilimumab, peanut or soy or any other trial drug, or their excipients
Hypersensitivity (not including renal dysfunction or eye disorder) to CDV or to BCV or its formulation excipients
Patient has a known history of hypersensitivity to defibrotide or any of the excipients.
Hypersensitivity to ipilimumab or nivolumab or any of their excipients
Hypersensitivity to PBZ or any of its excipients
Has hypersensitivity to either study drug or any of the excipients.
Hypersensitivity to nivolumab, ipilimumab, or any of its excipients
Hypersensitivity to nivolumab or ipilimumab or any of its excipients
Patients with known hypersensitivity to -azacitdine or MK or any of their excipients
Known hypersensitivity to any of the excipients of ribociclib or bicalutamide.
Known hypersensitivity to any of the excipients of ribociclib (LEE-)
Known hypersensitivity to pomalidomide, dexamethasone, or any excipients in elotuzumab, formulation, or recombinant protein
Known hypersensitivity to anetumab ravtansine, study drug classes or excipients in the formulation
Patients with a known hypersensitivity to any of the investigational agents or any of the excipients of the products
History of severe hypersensitivity reactions to paclitaxel or any of its excipients.
Patient has a known hypersensitivity to any of the excipients of ribociclib, aromatase inhibitors (such as letrozole) or fulvestrant
Hypersensitivity to nivolumab or lenalidomide or any of their excipients
Hypersensitivity to ruxolitinib or any of its excipients
Known hypersensitivity to any of the excipients of ribociclib or doxorubicin
Known hypersensitivity to afatinib or its excipients
Known hypersensitivity to GT or its excipients.
Known or possible hypersensitivity to palbociclib, fulvestrant, goserelin (if applicable) or to any of their excipients
Known hypersensitivity to letrozole or fulvestrant, or any of its excipients, or to any palbociclib excipients
Known hypersensitivity to exemestane or its excipients
Known hypersensitivity to nintedanib, any other trial drug, or their excipients
Known hypersensitivity to lenalidomide, dexamethasone, any excipients in the elotuzumab formulation (sodium citrate, citric acid, sucrose and polysorbate ) or recombinant protein
Patient has known hypersensitivity to any of the excipients of ribociclib
Known hypersensitivity to S-equol or any of its excipients
History of hypersensitivity to active or inactive excipients of any component of treatment
Patients with a known hypersensitivity to BKM or to its excipients
Known hypersensitivity to bevacizumab or any of its excipients or any other study drug
Hypersensitivity to decitabine, guadecitabine, or any of their excipients.
Has hypersensitivity to eribulin or any of the excipients
Known hypersensitivity to ASN or its excipients;
History of allergy or hypersensitivity to any systemically administered antibody agent or its excipients
hypersensitivity to the active substance or to any of the excipients of study drug;
Known hypersensitivity to any of the excipients of INC
Patients with a known hypersensitivity to BKM or to its excipients
Subjects to receive ofatumumab: hypersensitivity to ofatumumab or its excipients.
Known hypersensitivity to MMB, its metabolites, or formulation excipients
Patients with a known hypersensitivity to the testosterone cypionate or any of the excipients of the product
Known hypersensitivity or intolerance to any of the active substance or excipients in the formulations for pembrolizumab and blinatumomab
Known hypersensitivity to irinotecan or its excipients.
Known or possible hypersensitivity to fulvestrant, or palbociclib or any of their excipients.
Patients with hypersensitivity to mannitol are not eligible; patients who have known hypersensitivity to peanut or soya, any other trial drug, or their excipients, or to contrast media are not eligible
Patient has a known hypersensitivity to any of the excipients of BYL and/or enzalutamide.
Patient has a known hypersensitivity to any of the excipients of BYL (alpelisib)
Hypersensitivity to decitabine, guadecitabine, or any of their excipients.
Known hypersensitivity to ledipasvir, sofosbuvir, or formulation excipients
Patient has a known hypersensitivity to any of the excipients of buparlisib
Patient has a known hypersensitivity to ribociclib or excipients of tamoxifen
Patient has known hypersensitivity to any of the excipients of ribociclib
Patients with hypersensitivity to excipients of the study drug are not eligible
Hypersensitivity to erlotinib or alectinib or to any of the excipients.
Subject has a known hypersensitivity to any of the excipients of nivolumab, cisplatin or romidepsin
Known severe hypersensitivity reactions to compounds similar to palbociclib or palbociclib/placebo excipients or to endocrine treatments.
Known hypersensitivity to any excipients of tesevatinib.
Participants who had a prior exposure to trabectedin or hypersensitivity to any of the excipients will not be excluded from receiving single-agent Doxil
Patient has a known hypersensitivity to any of the excipients of ribociclib
Have a known or suspected hypersensitivity to brigatinib or its excipients and/or crizotinib or its excipients.
Known hypersensitivity to momelotinib, its metabolites, or formulation excipients
Hypersensitivity to the active ingredient or any of the excipients including lactose.
History of severe hypersensitivity reaction to study treatments or their excipients.
Known hypersensitivity to the study drugs (GS , fulvestrant or exemestane), the metabolites, or formulation excipients
Patient has a known hypersensitivity to Ribociclib or any of its excipients.
Have known intolerance to the Test Article (ie, documented hypersensitivity AE to prior monoclonal antibody therapy, or to amatuximab or any of its excipients)
Known hypersensitivity to any of the excipients of the investigational products
Patient has a known hypersensitivity to any of the excipients of ribociclib or letrozole
Known intolerance or hypersensitivity to progesterone or its excipients
Patients with a known hypersensitivity to ribociclib or everolimus or to its excipients.
Prior treatment with nintedanib (BIBF); known hypersensitivity to nintedanib, peanut or soya or any other trial drug, their excipients or to contrast media
No known hypersensitivity to BIBF , to its excipients or to contrast media
Patient has a known hypersensitivity to LEE or any of its excipients
History of hypersensitivity to any excipients in the investigational product.
No known severe hypersensitivity reactions to compounds similar to palbociclib or palbociclib excipients or to endocrine treatments.
Patient has a known hypersensitivity to any of the excipients of BYL
Hypersensitivity to chlorambucil, obinutuzumab, or venetoclax or to any of the excipients
Patients with a known hypersensitivity to BKM or to its excipients
Have a known or suspected hypersensitivity to brigatinib or its excipients.
Patients with a known hypersensitivity to BKM or its excipients
Hypersensitivity to ofatumumab or its excipients
Known hypersensitivity to any of the study treatments or to excipients of recombinant human or humanized antibodies
Hypersensitivity to any of the study medications or any of the ingredients or excipients of these medications, including hypersensitivity to benzyl alcohol
Patients with a known hypersensitivity to pazopanib or topotecan or to their excipients
Patient with a history of severe hypersensitivity reaction to pemetrexed or docetaxel or any known excipients of these drugs.
Patients with a known hypersensitivity to BKM or to its excipients, or hypersensitivity to cetuximab
Known severe hypersensitivity to tadalafil or any of the excipients of this product
Patients with a known hypersensitivity to vinorelbine or to its excipients
For Part C, have a known hypersensitivity to sorafenib or its excipients
Known hypersensitivity or intolerance to any of the active substances or excipients in the formulations for idelalisib, obinutuzumab, or chlorambucil
Known hypersensitivity to idelalisib, its metabolites, or formulation excipients
Patients with a known hypersensitivity to buparlisib or to its excipients
Hypersensitivity to erlotinib, crizotinib or to any of the excipients
Known hypersensitivity to bevacizumab or any of its excipients or any other study drug
Known severe hypersensitivity to ketoconazole, calcitriol or any of the excipients of these products
Patient has a known hypersensitivity to any of the excipients of PQR.
Any contraindication, allergy, or hypersensitivity to rociletinib, trametinib, or excipients
Known hypersensitivity or intolerance to any of the active substances or excipients in the formulations for ENTO
Known hypersensitivity to the study investigational medicinal product (IMP), the metabolites, or formulation excipients
Known hypersensitivity to the study drug or excipients of the preparation or any agent given in association with this study
Known hypersensitivity/allergy to fluconazole or itraconazole or their respective excipients.
Known hypersensitivity to the study drug or excipients of the preparation or any agent given in association with this study
Known hypersensitivity to chlorambucil or any of its excipients
Known hypersensitivity to compounds related to orteronel or to orteronel excipients
Subjects with hypersensitivity (not renal dysfunction or eye disorder) to CDV or to CMX or its excipients.
Known hypersensitivity to BKM or to its excipients
Known hypersensitivity to the active substance or to any of the excipients in the vaccine
Patients with a known hypersensitivity to BKM or to its excipients
Known severe hypersensitivity to or any of the excipients of this product.
Patient has a known hypersensitivity to any of the excipients of BKM
No known serious or severe hypersensitivity reaction to naloxegol or any of its excipients
Known or suspected hypersensitivity or intolerance to fentanyl or hydromorphone or excipients in the study medications
History of hypersensitivity to any excipients in the quizartinib/placebo tablets;
Known hypersensitivity to ASN or its excipients;
Known hypersensitivity to recombinant ESAs or the excipients contained within the investigational product.
Patients with allergy, hypersensitivity or other contraindication to dapsone, sulfa antibiotics, or excipients of the dapsone gel product
Patient has a known history of hypersensitivity to defibrotide or any of the excipients.
Patient has a known hypersensitivity to the administration of rolapitant or its excipients
Hypersensitivity to NVB or any of its excipients or to any component of AVD + BV therapy
Hypersensitivity to decitabine, SGI-, or SGI- excipients.
Known hypersensitivity to the study drug or excipients of the preparation or any agent given in association with this study
